Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Specimen Handling 640 pembrolizumab 570 Magnetic Resonance Spectroscopy 550 Carboplatin 430 Cyclophosphamide 382 Cisplatin 376 Biopsy 364 Paclitaxel 312 Nivolumab 310 Gemcitabine 302 Radiotherapy 275 Bevacizumab 243 Dexamethasone 213 fludarabine 209 Docetaxel 193 durvalumab 182 atezolizumab 179 Oxaliplatin 173 Rituximab 168 Fluorouracil 168 venetoclax 167 Pemetrexed 165 Doxorubicin 163 Radiation 161 Capecitabine 161 Radiosurgery 149 Etoposide 138 Ipilimumab 136 Leucovorin 134 Lenalidomide 133

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

DLL3 protein, human × 90 days × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡